# GNPTAB

## Overview
The GNPTAB gene encodes the alpha and beta subunits of the enzyme N-acetylglucosamine-1-phosphate transferase, a critical component in the lysosomal enzyme targeting pathway. This enzyme is responsible for the initial step in the formation of mannose 6-phosphate (M6P) markers on glycoproteins, which are essential for directing lysosomal enzymes to their appropriate cellular destinations. The protein encoded by GNPTAB is a transmembrane enzyme that functions within the Golgi apparatus, where it modifies lysosomal enzymes to ensure their proper transport to lysosomes. This process is vital for cellular homeostasis, as lysosomes play a key role in degrading macromolecules. Mutations in GNPTAB can lead to lysosomal storage disorders such as mucolipidosis types II and III, highlighting the gene's clinical significance (Di2021Pathogenic; De2015Subunit; Otomo2009Mucolipidosis).

## Structure
The GNPTAB gene encodes the α/β-subunit precursor of the enzyme N-acetylglucosamine-1-phosphate transferase, which is essential for lysosomal enzyme targeting. The precursor protein consists of 1256 amino acids and includes two transmembrane domains located at the amino and carboxyl termini, which are crucial for the α/β cleavage necessary for the enzyme's activity (Braulke2008Molecular; Tappino2009Molecular). 

The protein's structure features several functional domains, including a bacterial capsular polymerase-like domain, Notch receptor repeats, and a DNA methyltransferase-associated protein (DMAP) domain (Tappino2009Molecular; Velho2019The). The α-subunit contains luminal Notch repeat-like domains and a DMAP domain, which are involved in binding lysosomal enzymes (Danyukova2019Combined). 

The GNPTAB protein forms a hexameric complex with a 2:2:2 molar ratio of α, β, and γ subunits, with the γ subunit encoded by the GNPTG gene (Braulke2008Molecular; Velho2019The). The α/β-precursor is synthesized in the endoplasmic reticulum and transported to the Golgi apparatus, where it is cleaved into active α and β subunits by site-1 protease (S1P) (Velho2015Analyses; Velho2019The). 

Post-translational modifications include glycosylation, with the mature α and β subunits containing 16 and 3 potential N-glycosylation sites, respectively (Braulke2008Molecular). The protein's structure is conserved across several species, including humans, mice, and zebrafish (Braulke2008Molecular).

## Function
The GNPTAB gene encodes the alpha and beta subunits of the enzyme N-acetylglucosamine-1-phosphate transferase, which is crucial for the lysosomal targeting of hydrolases. This enzyme catalyzes the first step in the formation of mannose 6-phosphate (M6P) markers on glycoproteins, a process essential for directing lysosomal enzymes to their proper cellular destination. In healthy human cells, GNPTAB is active in the Golgi apparatus, where it modifies newly synthesized lysosomal enzymes by adding M6P markers. These markers are recognized by specific receptors that facilitate the transport of enzymes to lysosomes, where they degrade macromolecules, thus maintaining cellular homeostasis (Di2021Pathogenic; De2015Subunit).

The GNPTAB gene is also involved in the regulation of melanogenesis in hair follicle melanocytes. It ensures the proper sorting and transportation of tyrosinase, a key enzyme in melanin production, to melanosomal compartments. This process is vital for maintaining normal pigmentation in hair follicles (Tiede2021UDPGlcNAc1Phosphotransferase). Additionally, GNPTAB plays a role in bone health by regulating osteoclast activity and bone resorption, which is crucial for maintaining skeletal integrity (Di2021Pathogenic).

## Clinical Significance
Mutations in the GNPTAB gene are responsible for mucolipidosis types II (ML II) and III (ML III), which are autosomal recessive lysosomal storage disorders. These conditions arise from deficiencies in the enzyme N-acetylglucosamine-1-phosphotransferase, leading to improper targeting of lysosomal enzymes and their subsequent accumulation in the extracellular space (Velho2019The; Otomo2009Mucolipidosis). ML II, also known as I-cell disease, is characterized by severe symptoms such as growth retardation, coarse facial features, skeletal abnormalities, and early childhood mortality (Mao2022Case; Yang2013Two). In contrast, ML III, or pseudo-Hurler polydystrophy, presents with milder symptoms and allows for survival into adulthood (Mao2022Case; Velho2019The).

The severity of these disorders is linked to the type of mutation in the GNPTAB gene. Nonsense and frameshift mutations typically result in a severe ML II phenotype, while missense mutations are often associated with the milder ML III phenotype (HashemiGorji2016A; Tappino2009Molecular). Genetic analysis is crucial for diagnosis, especially in regions where enzyme activity detection is limited (Mao2022Case).

## Interactions
The GNPTAB gene encodes the alpha and beta subunits of the GlcNAc-1-phosphotransferase complex, which is crucial for lysosomal enzyme targeting. This complex is a hexamer composed of two alpha, two beta, and two gamma subunits. The alpha and beta subunits, encoded by GNPTAB, are responsible for the catalytic activity of the enzyme, while the gamma subunit, encoded by GNPTG, enhances the phosphorylation of protein substrates (Qian2010Functions).

The alpha subunit contains a GNPTG binding (GB) domain, which is essential for the interaction with the gamma subunit. This interaction is critical for the enzyme's activity, as the loss of gamma subunit binding significantly reduces the enzyme's function (De2015Subunit). The alpha subunits form disulfide-linked homodimers via cysteine 70, although this dimerization is not necessary for gamma subunit interaction (De2015Subunit).

Mutations in GNPTAB can disrupt these interactions, leading to diseases such as mucolipidosis II and III. Some mutations affect the enzyme's ability to exit the endoplasmic reticulum and reach the Golgi apparatus, impacting its function and leading to varying disease phenotypes (Velho2015Analyses). The gamma subunit's mannose 6-phosphate receptor homology (MRH) domain is likely responsible for its selective interaction with glycosylated regions of the alpha subunit, further influencing the enzyme's activity (De2015Subunit).


## References


[1. (HashemiGorji2016A) Feyzollah Hashemi-Gorji, Soudeh Ghafouri-Fard, Shadab Salehpour, Vahid Reza Yassaee, and Mohammad Miryounesi. A novel splice site mutation in the gnptab gene in an iranian patient with mucolipidosis ii α/β. Journal of Pediatric Endocrinology and Metabolism, 29(8):991–993, May 2016. URL: http://dx.doi.org/10.1515/jpem-2016-0032, doi:10.1515/jpem-2016-0032. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1515/jpem-2016-0032)

[2. (Di2021Pathogenic) Giorgia Di Lorenzo, Lena M. Westermann, Timur A. Yorgan, Julian Stürznickel, Nataniel F. Ludwig, Luise S. Ammer, Anke Baranowsky, Shiva Ahmadi, Elham Pourbarkhordariesfandabadi, Sandra R. Breyer, Tim N. Board, Anne Foster, Jean Mercer, Karen Tylee, Renata Voltolini Velho, Michaela Schweizer, Thomas Renné, Thomas Braulke, Dévora N. Randon, Fernanda Sperb-Ludwig, Louise Lapagesse de Camargo Pinto, Carolina Araujo Moreno, Denise P. Cavalcanti, Michael Amling, Kerstin Kutsche, Dominic Winter, Nicole M. Muschol, Ida V.D. Schwartz, Tim Rolvien, Tatyana Danyukova, Thorsten Schinke, and Sandra Pohl. Pathogenic variants in gnptab and gnptg encoding distinct subunits of glcnac-1-phosphotransferase differentially impact bone resorption in patients with mucolipidosis type ii and iii. Genetics in Medicine, 23(12):2369–2377, December 2021. URL: http://dx.doi.org/10.1038/s41436-021-01285-9, doi:10.1038/s41436-021-01285-9. This article has 2 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41436-021-01285-9)

[3. (Velho2015Analyses) R. V. Velho, R. De Pace, S. Klunder, F. Sperb-Ludwig, C. M. Lourenco, I. V. D. Schwartz, T. Braulke, and S. Pohl. Analyses of disease-related gnptab mutations define a novel glcnac-1-phosphotransferase interaction domain and an alternative site-1 protease cleavage site. Human Molecular Genetics, 24(12):3497–3505, March 2015. URL: http://dx.doi.org/10.1093/hmg/ddv100, doi:10.1093/hmg/ddv100. This article has 23 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddv100)

[4. (Tappino2009Molecular) Barbara Tappino, Nadia A. Chuzhanova, Stefano Regis, Andrea Dardis, Fabio Corsolini, Marina Stroppiano, Emmanuel Tonoli, Tommaso Beccari, Camillo Rosano, Jan Mucha, Mariana Blanco, Marina Szlago, Maja Di Rocco, David N. Cooper, and Mirella Filocamo. Molecular characterization of 22 novel udp-n-acetylglucosamine-1-phosphate transferase α- and β-subunit (gnptab) gene mutations causing mucolipidosis types iiα/β and iiiα/β in 46 patients. Human Mutation, 30(11):E956–E973, November 2009. URL: http://dx.doi.org/10.1002/humu.21099, doi:10.1002/humu.21099. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.21099)

[5. (Braulke2008Molecular) T. Braulke, S. Pohl, and S. Storch. Molecular analysis of the glcnac‐1‐phosphotransferase. Journal of Inherited Metabolic Disease, 31(2):253–257, April 2008. URL: http://dx.doi.org/10.1007/s10545-008-0862-5, doi:10.1007/s10545-008-0862-5. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10545-008-0862-5)

[6. (Mao2022Case) Shao-Jia Mao, Yu-Mei Zu, Yang-Li Dai, and Chao-Chun Zou. Case report: mucolipidosis ii and iii alpha/beta caused by pathogenic variants in the gnptab gene (mucolipidosis). Frontiers in Pediatrics, April 2022. URL: http://dx.doi.org/10.3389/fped.2022.852701, doi:10.3389/fped.2022.852701. This article has 1 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fped.2022.852701)

[7. (Tiede2021UDPGlcNAc1Phosphotransferase) Stephan Tiede, Jennifer E. Hundt, and Ralf Paus. Udp-glcnac-1-phosphotransferase is a clinically important regulator of human and mouse hair pigmentation. Journal of Investigative Dermatology, 141(12):2957-2965.e5, December 2021. URL: http://dx.doi.org/10.1016/j.jid.2021.04.028, doi:10.1016/j.jid.2021.04.028. This article has 7 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.jid.2021.04.028)

[8. (Otomo2009Mucolipidosis) Takanobu Otomo, Takeshi Muramatsu, Tohru Yorifuji, Torayuki Okuyama, Hiroki Nakabayashi, Toshiyuki Fukao, Toshihiro Ohura, Makoto Yoshino, Akemi Tanaka, Nobuhiko Okamoto, Koji Inui, Keiichi Ozono, and Norio Sakai. Mucolipidosis ii and iii alpha/beta: mutation analysis of 40 japanese patients showed genotype–phenotype correlation. Journal of Human Genetics, 54(3):145–151, February 2009. URL: http://dx.doi.org/10.1038/jhg.2009.3, doi:10.1038/jhg.2009.3. This article has 56 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/jhg.2009.3)

[9. (Danyukova2019Combined) Tatyana Danyukova, Nataniel F. Ludwig, Renata V. Velho, Frederike L. Harms, Nilay Güneş, Henning Tidow, Ida V. Schwartz, Beyhan Tüysüz, and Sandra Pohl. Combined in vitro and in silico analyses of missense mutations in gnptab provide new insights into the molecular bases of mucolipidosis ii and iii alpha/beta. Human Mutation, 41(1):133–139, October 2019. URL: http://dx.doi.org/10.1002/humu.23928, doi:10.1002/humu.23928. This article has 6 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.23928)

[10. (Yang2013Two) Yao Yang, Jian Wu, Haihong Liu, Xiaochun Chen, Ying Wang, Mancang Zhao, and Xiyu He. Two homozygous nonsense mutations of gnptab gene in two chinese families with mucolipidosis ii alpha/beta using targeted next-generation sequencing. Genomics, 102(3):169–173, September 2013. URL: http://dx.doi.org/10.1016/j.ygeno.2013.06.001, doi:10.1016/j.ygeno.2013.06.001. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ygeno.2013.06.001)

[11. (Qian2010Functions) Yi Qian, Intaek Lee, Wang-Sik Lee, Meiqian Qian, Mariko Kudo, William M. Canfield, Peter Lobel, and Stuart Kornfeld. Functions of the α, β, and γ subunits of udp-glcnac:lysosomal enzyme n-acetylglucosamine-1-phosphotransferase. Journal of Biological Chemistry, 285(5):3360–3370, January 2010. URL: http://dx.doi.org/10.1074/jbc.m109.068650, doi:10.1074/jbc.m109.068650. This article has 59 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m109.068650)

[12. (De2015Subunit) Raffaella De Pace, Renata Voltolini Velho, Marisa Encarnação, Katrin Marschner, Thomas Braulke, and Sandra Pohl. Subunit interactions of the disease-related hexameric glcnac-1-phosphotransferase complex. Human Molecular Genetics, 24(23):6826–6835, September 2015. URL: http://dx.doi.org/10.1093/hmg/ddv387, doi:10.1093/hmg/ddv387. This article has 20 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddv387)

[13. (Velho2019The) Renata Voltolini Velho, Frederike L. Harms, Tatyana Danyukova, Nataniel F. Ludwig, Michael J. Friez, Sara S. Cathey, Mirella Filocamo, Barbara Tappino, Nilay Güneş, Beyhan Tüysüz, Karen L. Tylee, Kathryn L. Brammeier, Lesley Heptinstall, Esmee Oussoren, Ans T. Ploeg, Christine Petersen, Sandra Alves, Gloria Durán Saavedra, Ida V. Schwartz, Nicole Muschol, Kerstin Kutsche, and Sandra Pohl. The lysosomal storage disorders mucolipidosis type ii, type iii alpha/beta, and type iii gamma: update ongnptabandgnptgmutations. Human Mutation, April 2019. URL: http://dx.doi.org/10.1002/humu.23748, doi:10.1002/humu.23748. This article has 13 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.23748)